Billionaire Stanley Druckenmiller's 2 New Healthcare Stock Picks
Stanley Druckenmiller's Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 372 | $35,420 | -28% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | $201,713.00 | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | $9,999,996.42 | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | $9,350,000.00 | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.19 | 2,300 | $241,937.00 | 239,258 | 2026-09-14 | Filing | |
| $104.55 | 1,817 | $189,964.99 | 241,558 | 2026-09-14 | Filing | |
| $103.43 | 8,698 | $899,634.14 | 243,375 | 2026-09-14 | Filing | |
| $102.35 | 30,746 | $3,146,760.86 | 252,073 | 2026-09-14 | Filing | |
| $101.75 | 6,439 | $655,145.07 | 282,819 | 2026-09-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 976,487 | $93,018,696 | 0.09% | |
| 2. | 363,373 | $34,598,560 | 0.03% | |
| 3. | 352,278 | $33,664,701 | 0.15% | |
| 4. | 50,166 | $4,776,556 | 0.45% | |
| 5. | 35,517 | $3,381,758 | 0% |
News See All
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list.
10 Best Biotech Stocks to Buy According to Analysts
In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy According to Analysts.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
In this article, we will look at the 10 Most Promising Healthcare Stocks According to Wall Street Analysts.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript May 5, 2026Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.83, expectations were $-0.86.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?
Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bears’ thesis on RYTM.
15 Most Promising Stocks Under $100 to Buy
In this article, we will discuss the 15 Most Promising Stocks Under $100 to Buy.
Top 10 Boring Stocks That Make Money
In this article, we will be taking a look at the Top 10 Boring Stocks That Make Money.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript February 26, 2026Rhythm Pharmaceuticals, Inc. beats earnings expectations.